About the Study

Neuroblastoma: A study of DFMO as maintenance therapy

This study is for: • Patients who are between the ages of 0 and 21 years old • Who have been diagnosed with high-risk neuroblastoma (HRNB) that is now in remission and no longer seen as active disease on scans and in bone marrow samples. • Who have completed prior treatment for HRNB The goal this study is to find what effects, good and/or bad, the investigational drug eflornithine HCl (DFMO) has on neuroblastoma that is in remission (cured according to medical tests). An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). This study will look at the ability of this study drug to keep tumors in remission and will also look at the safety and tolerability of DFMO.

Interested in learning more?

Full Study Name: NMTRC014 NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)